Pharmacogenetics of Opioid Use Disorder Treatment

Brady KT, McCauley JL, Back SE. Prescription opioid misuse, abuse, and treatment in the united states: an update. Am J Psychiatry. 2016;173(1):18–26. Han B, et al. Prescription opioid use, misuse, and use disorders in US adults: 2015 National survey on drug use and health. Ann Intern Med. 2017;167(5):293–301. Martell BA, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116–27. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 2013;132(1–2):95–100. Birnbaum HG, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657–67. Florence CS, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–6. Jiang R, et al. The societal cost of heroin use disorder in the United States. PLoS One. 2017;12(5):e0177323. Novak SP, et al. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry. 2016;16:274. United Nations Office on Drugs and Crime. World Drug Report 2017, United Nations publication. ISBN: 978-92-1-148291-1 Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. https://doi.org/10.1002/14651858.CD002207.pub2. Degenhardt L, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306–17. Gowing L, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):CD004145. https://doi.org/10.1002/14651858.CD004145.pub4. Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2(4):395–402. Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil. 2015;6:1–14. Minozzi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333. https://doi.org/10.1002/14651858.CD001333.pub4. Kirchmayer U, et al. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction. 2002;97(10):1241–9. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101(4):491–503. Krupitsky E, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628–37. Krupitsky E, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–93. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2 Suppl):S39–47. McCance-Katz EF, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007;91(2–3):269–78. Hser YI, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87. Brewer DD, et al. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998;93(1):73–92. Clark RE, et al. Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75–80. Yin W, et al. Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China. Addiction. 2015;110(Suppl 1):51–60. Ferri M, et al. Predictive factors for relapse in patients on buprenorphine maintenance. Am J Addict. 2014;23(1):62–7. Weinstein ZM, et al. Long-term retention in Office Based Opioid Treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65–70. Bouer R, et al. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol. 1999;13(4):494–500. Rodriguez M, et al. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol. 2004;56(3):367–74. Coller JK, et al. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006;80(6):682–90. Levran O, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008;17(14):2219–27. Kim RB, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70(2):189–99. Hung CC, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011;12(11):1525–33. Crettol S, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80(6):668–81. Csajka C, et al. Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in OPIOID-DEPENDENT PATIENTS. Clin Pharmacokinet. 2016;55(12):1521–33. Crettol S, et al. No influence of ABCB1 haplotypes on methadone dosage requirement. Clin Pharmacol Ther. 2008;83(5):668–9 (author reply 669–70). Fonseca F, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011;6(5):e19527. Mouly S, et al. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015;79(6):967–77. Buchard A, et al. Postmortem blood concentrations of R- and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and p-glycoprotein genotype. J Forensic Sci. 2010;55(2):457–63. Lee HY, et al. Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan. Biomed Res Int. 2013;2013:741403. Luo R, et al. Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients. Pharmacogenomics. 2017;18(18):1659–70. Dennis BB, et al. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One. 2014;9(1):e86114. Bart G, et al. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014;145:185–93. Zahari Z, et al. Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse. 2016;42(5):587–96. van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem. 1999;36(Pt 6):722–9. Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688–700. Gaedigk A, et al. The pharmacogene variation (pharmvar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2017;103(3):399–401. Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol. 2013;53(3):305–13. Kharasch ED, et al. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2015;123(5):1142–53. Levran O, et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol. 2013;18(4):709–16. Tsai HJ, et al. Assessment of CYP450 genetic variability effect on methadone dose and tolerance. Pharmacogenomics. 2014;15(7):977–86. Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91. Crettol S, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78(6):593–604. Wang SC, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol. 2011;31(4):463–9. Dobrinas M, et al. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet Genomics. 2013;23(2):84–93. Bunten H, et al. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther. 2010;88(3):383–9. Totah RA, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology. 2008;108(3):363–74. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16(1):36–44. Shinderman M, et al. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend. 2003;69(2):205–11. Shiran MR, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2009;67(1):29–37. Shiran MR, et al. Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol. 2012;32(5):666–71. Eap CB, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol. 2001;21(2):229–34. Kringen MK, et al. Combined effect of CYP2B6 genotype and other candidate genes on a steady-state serum concentration of methadone in opioid maintenance treatment. Ther Drug Monit. 2017;39(5):550–5. Coller JK, et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int J Clin Pharmacol Ther. 2007;45(7):410–7. Lotsch J, et al. A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenet Genomics. 2010;20(5):291–7. Levran O, et al. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013;14(7):755–68. Barratt DT, et al. ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmgenomics Pers Med. 2012;5:53–62. Smith AH, et al. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Mol Psychiatry. 2017;22(3):346–52. Yang HC, et al. Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients. PLoS Genet. 2016;12(3):e1005910. Burstyn-Cohen T, et al. F-Spondin is required for accurate pathfinding of commissural axons at the floor plate. Neuron. 1999;23(2):233–46. Gu X, et al. GSG1L suppresses AMPA receptor-mediated synaptic transmission and uniquely modulates AMPA receptor kinetics in hippocampal neurons. Nat Commun. 2016;7:10873. Iribarne C, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997;60(22):1953–64. Moody DE, et al. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002;306(1):31–9. Picard N, et al. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005;33(5):689–95. Crist RC, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013;38(10):2003–10. Crist RC, et al. A polymorphism in the OPRM1 3’-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J. 2018;18(1):173–9. Kuo HW, et al. Pharmacogenomics study on cadherin 2 network with regard to HIV infection and methadone treatment outcome. PLoS One. 2017;12(3):e0174647. Arikkath J, Reichardt LF. Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity. Trends Neurosci. 2008;31(9):487–94. Nelson EC, et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry. 2016;21(5):608–14. Fonseca F, et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther. 2010;14(3):171–8. Fonseca F, et al. ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. Eur Neuropsychopharmacol. 2014;24(3):420–4. Oneda B, et al. beta-Arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 2011;11(4):258–66. Crettol S, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1722–7. Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(4):323–31. Bawor M, et al. Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study. Addict Sci Clin Pract. 2015;10:19. Lawford BR, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet. 2000;96(5):592–8. de Cid R, et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav. 2008;7(5):515–22. Wang SC, et al. The association of genetic polymorphisms in the kappa-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. J Clin Psychopharmacol. 2014;34(2):205–11. Tian JN, et al. UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics. 2012;13(8):879–88. de los Cobos JP, et al. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend. 2007;89(2–3):190–4. de los Cobos JP, et al. Satisfaction With methadone and opioid receptor genes polymorphisms in treatment-refractory heroin-dependent patients. J Clin Psychopharmacol. 2017;37(3):378–80. Clarke TK, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J. 2014;14(3):303–8. Zhu Y, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron. 1999;24(1):243–52. Nelson EC, et al. Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol. 2014;19(1):111–21. Gerra G, et al. Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Res. 2014;215(1):202–7. Evans E, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006–10. Addiction. 2015;110(6):996–1005. Concool B, Smith H, Stimmel B. Mortality rates of persons entering methadone maintenance: a seven-year study. Am J Drug Alcohol Abuse. 1979;6(3):345–53. Richards-Waugh LL, et al. Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism. J Anal Toxicol. 2014;38(8):541–7. Ahmad T, et al. Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities. J Anal Toxicol. 2017;41(4):325–33. Bunten H, et al. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol. 2011;16(1):142–4. Anchersen K, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104(6):993–9. Baker JR, et al. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother. 2006;40(3):392–6. Harris SC, et al. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80. Krantz MJ. Heterogeneous impact of methadone on the QTc interval: what are the practical implications? J Addict Dis. 2008;27(4):5–9. Eap CB, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81(5):719–28. Carlquist JF, et al. A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study. Mol Diagn Ther. 2015;19(2):131–8. Wang SC, et al. Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. OMICS. 2013;17(10):519–26. Katchman AN, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther. 2002;303(2):688–94. Hajj A, et al. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug Alcohol Depend. 2014;141:34–8. Marjamaa A, et al. High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med. 2009;41(3):234–40. Wang SC, et al. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. Eur Neuropsychopharmacol. 2012;22(10):695–703. Sharafshah A, et al. Association of OPRD1 gene variants with opioid dependence in addicted male individuals undergoing methadone treatment in the North of Iran. J Psychoactive Drugs. 2017;49(3):242–51. Albonaim A, et al. Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population. J Addict Dis. 2017;36(4):227–35.